During the last session, Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares were 1.07 million, with the beta value of the company hitting 0.39. At the end of the trading day, the stock’s price was $2.24, reflecting an intraday gain of 4.19% or $0.09. The 52-week high for the TSHA share is $4.32, that puts it down -92.86 from that peak though still a striking 43.3% gain since the share price plummeted to a 52-week low of $1.27. The company’s market capitalization is $459.07M, and the average intraday trading volume over the past 10 days was 0.89 million shares, and the average trade volume was 2.48 million shares over the past three months.
Taysha Gene Therapies Inc (TSHA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.09. TSHA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Taysha Gene Therapies Inc (TSHA) registered a 4.19% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.19% in intraday trading to $2.24, hitting a weekly high. The stock’s 5-day price performance is 1.82%, and it has moved by 3.70% in 30 days. Based on these gigs, the overall price performance for the year is -31.71%. The short interest in Taysha Gene Therapies Inc (NASDAQ:TSHA) is 20.78 million shares and it means that shorts have 14.84 day(s) to cover.
The consensus price target of analysts on Wall Street is $8.5, which implies an increase of 73.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $44 respectively. As a result, TSHA is trading at a discount of -1864.29% off the target high and -123.21% off the low.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics show that Taysha Gene Therapies Inc has outperformed its competitors in share price, compared to the industry in which it operates. Taysha Gene Therapies Inc (TSHA) shares have gone down -30.65% during the last six months, with a year-to-date growth rate more than the industry average at 63.54% against 21.80. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 90.30% this quarter and then drop -109.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -45.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.65M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 2.33M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 4.75M and 3.6M respectively. In this case, analysts expect current quarter sales to shrink by -65.20% and then drop by -35.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -137.69%. While earnings are projected to return 61.72% in 2024.
TSHA Dividends
Taysha Gene Therapies Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Taysha Gene Therapies Inc insiders own 17.54% of total outstanding shares while institutional holders control 77.56%, with the float percentage being 94.06%. FMR LLC is the largest shareholder of the company, while 143.0 institutions own stock in it. As of 2024-06-30, the company held over 21.21 million shares (or 9.1722% of all shares), a total value of $47.51 million in shares.
The next largest institutional holding, with 18.8 million shares, is of RTW INVESTMENTS, LP’s that is approximately 8.1299% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.11 million.
